Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 20;59(10):e0110721.
doi: 10.1128/JCM.01107-21. Epub 2021 Aug 4.

A Real-World Comparison of SARS-CoV-2 Rapid Antigen Testing versus PCR Testing in Florida

Lao-Tzu Allan-Blitz  1 , Jeffrey D Klausner  2
Affiliations

A Real-World Comparison of SARS-CoV-2 Rapid Antigen Testing versus PCR Testing in Florida

Lao-Tzu Allan-Blitz et al. J Clin Microbiol. .

Abstract

The reported sensitivity of rapid, antigen-based diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection varies. Few studies have evaluated rapid antigen tests in real-world settings or among large populations. Beginning October 2020, Florida offered individuals presenting for SARS-CoV-2 testing PCR testing if they tested positive by the Abbott BinaxNOW COVID-19 antigen (Ag) card, were symptomatic, or required or requested PCR testing. We compared results among individuals who received both types of tests at four publicly accessible testing sites across Florida. We calculated the positive percent agreement (PPA) between the two test types by symptom status. Subsequently, we evaluated the PPA among individuals regardless of symptoms with lower cycle threshold values (<30). Overall, 18,457 individuals were tested via both methods, of which 3,153 (17.1%) were positive by PCR. The PPA for the Abbott BinaxNOW COVID-19 Ag card using the PCR comparator was 49.2% (95% confidence interval [CI], 47.4% to 50.9%). Among symptomatic individuals the PPA was 51.9% (95% CI, 49.7% to 54.0%). When restricted to positive PCR tests with a cycle threshold value of <30, regardless of symptom status, the PPA was 75.3% (95% CI, 72.8% to 77.6%). The PPA of the Abbott BinaxNOW COVID-19 Ag card compared with PCR was lower than that previously reported. Our findings may reflect the performance of the BinaxNOW antigen test in real-world settings.

Keywords: PCR; SARS-CoV-2; rapid antigen tests.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Abbott BinaxNOW COVID-19 Ag card results by SARS-CoV-2 viral cycle threshold value from a community-based sample in Florida, 2020.
See this image and copyright information in PMC

References

    1. Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. 2020. Asymptomatic SARS coronavirus 2 infection: invisible yet invincible. Int J Infect Dis 100:112–116. doi:10.1016/j.ijid.2020.08.076. - DOI - PMC - PubMed
    1. Abbott Diagnostics. 2020. Abbot BinaxNOW COVID-19 Ag package insert, version 1.6. https://www.fda.gov/media/141570/download. Accessed 12 December 2020.
    1. Pilarowski G, Marquez C, Rubio L, Peng J, Martinez J, Black D, Chamie G, Jones D, Jacobo J, Tulier-Laiwa V, Rojas S, Rojas S, Cox C, Petersen M, DeRisi J, Havlir DV. 26December2020. Field performance and public health response using the BinaxNOW Rapid SARS-CoV-2 antigen detection assay during community-based testing. Clin Infect Dis doi:10.1093/cid/ciaa1890. - DOI - PMC - PubMed
    1. Scohy A, Anantharajah A, Bodeus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. 2020. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. J Clin Virol 129:104455. doi:10.1016/j.jcv.2020.104455. - DOI - PMC - PubMed
    1. Kruttgen A, Cornelissen CG, Dreher M, Hornef MW, Imohl M, Kleines M. 2021. Comparison of the SARS-CoV-2 Rapid antigen test to the real star SARS-CoV-2 RT PCR kit. J Virol Methods 288:114024. doi:10.1016/j.jviromet.2020.114024. - DOI - PMC - PubMed

Substances